PARP1 and familial pancreatic carcinoma: In terms of targeted therapy, poly ADP-ribose polymerase (PARP) inhibitors have demonstrated superior efficacy in pancreatic cancer and hepatobiliary cancer patients carrying BRCA1/2 mutations [45, 48].